-0.040 (-4.52%)
Range 0.826 - 0.890   (7.75%)
Open 0.882
Previous Close 0.884
Buy Price 0.842
Buy Volume 11
Sell Price 0.855
Sell Volume 14
Volume 2,934,054
Value -
Measurement Type Value
EPS (USD) -0.837
Trailing EPS (USD) -1.338
NAV (USD) 0.722
Cash In Hand (USD) 0.668
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 1.246
Price / Cash In Hand 1.348
Issued & Paid-up Shares 112,743,000
Treasury Shares -
Market Cap (M) 101.503
Par Value (USD) n.a.
Beta - 75 Days 0.164
R-Squared - 75 Days(%) 0.07
Beta - 500 Days 0.888
R-Squared - 500 Days(%) 7.83
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 22 Jan 2022 05:00.
Data powered by

Upcoming Events

* Stock event date based on US timezone.


Release Date 07 Mar 2022
View All Events


Ardelyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of non-systemic, small molecule therapeutics that work in the gastrointestinal (GI), tract to treat cardio-renal, GI and metabolic diseases. The Company has developed a drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design drug candidates. Utilizing its platform, the Company discovered and designed its product candidate, tenapanor, which in preclinical and clinical studies has consistently demonstrated the ability to reduce the absorption of dietary sodium and phosphorus, both of which are key factors in the progression of kidney disease. The Company�s product candidate, tenapanor, is a small molecule, orally administered inhibitor of NHE3, a transporter of sodium in the GI tract. It and AstraZeneca AB (AstraZeneca) has evaluated tenapanor in eight human clinical trials in over 765 individuals.

Loading Chart...